Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues
China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...
WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...
Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China
China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...
Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...
Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study
Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products...
Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment
Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...
Fosun Pharma’s Proxima AI Raises Over RMB 100M in Strategic Financing
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology...
Taibang Biologic Raises $300M in Post-Privatization Financing Round
Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021,...
Sironax Completes $200 Million Series B Financing for Age-Related Disease Therapies
Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing...
ImmVira Partners with China Resources Biopharmaceutical on Oncolytic Virus MVR-C5252 for Gliomas
China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources...
Tus-Pharma to Acquire Sinotau Pharma for RMB 220 Million
China-based Tus-Pharmaceutical Group Co., Ltd (SHE: 000590) has announced plans to acquire 100% of Guangdong...
Eli Lilly Files for Baqsimi Approval in China to Treat Severe Hypoglycemia
Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center...
Aosaikang’s ASKG315 Receives Ethics Approval for Phase I Cancer Trial in Australia
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced it has received ethical approval from Australia’s...
Ablaze Pharma to Invest $100M in Chengdu TRT R&D and Manufacturing Hub
Shanghai-based Ablaze Pharma announced plans to invest an initial $100 million in a new research...
Astellas Pharma Posts 17% Q1 Sales Growth Driven by Xtandi and Padcev
Japan-based Astellas Pharma Inc. (TYO: 4503) reported a 17.1% year-on-year (YOY) increase in global sales...
Eli Lilly’s Taltz Wins Second NMPA Approval for Ankylosing Spondylitis
U.S. pharmaceutical giant Eli Lilly announced it has received a second marketing approval from the...
China Resources Double-Crane to Acquire Stake in Shenzhou Biotech for Bio-Fermentation Push
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced plans to acquire a 50.11% stake...